Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
J
MBP 82.0 Jevtana (cabazitaxel)
Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Reviewed 1/28/21
Related information
Learn more about Geisinger Health Plan.
Clinical guidelines
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.